Nkarta, Inc. (NKTX)
2.79
+0.02
(+0.90%)
USD |
NASDAQ |
Sep 03, 16:00
2.82
+0.03
(+1.08%)
Pre-Market: 08:25
Nkarta Cash from Investing (Quarterly) : 21.15M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 21.15M |
| March 31, 2026 | 15.92M |
| December 31, 2025 | 1.103M |
| September 30, 2025 | 25.39M |
| June 30, 2025 | 19.49M |
| March 31, 2025 | 54.34M |
| December 31, 2024 | -4.52M |
| September 30, 2024 | -38.90M |
| June 30, 2024 | -107.62M |
| March 31, 2024 | 21.48M |
| December 31, 2023 | 15.84M |
| September 30, 2023 | 29.42M |
| June 30, 2023 | -3.171M |
| March 31, 2023 | 36.93M |
| December 31, 2022 | 4.747M |
| Date | Value |
|---|---|
| September 30, 2022 | -79.11M |
| June 30, 2022 | -109.30M |
| March 31, 2022 | -1.026M |
| December 31, 2021 | -17.84M |
| September 30, 2021 | 91.51M |
| June 30, 2021 | -20.95M |
| March 31, 2021 | -20.19M |
| December 31, 2020 | -78.72M |
| September 30, 2020 | -139.07M |
| June 30, 2020 | 2.813M |
| March 31, 2020 | 4.898M |
| December 31, 2019 | -16.99M |
| September 30, 2019 | -0.6012M |
| June 30, 2019 | -0.2751M |
| March 31, 2019 | -0.4297M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 0.00 |
| Theriva Biologics, Inc. | -0.003M |
| Unicycive Therapeutics, Inc. | -0.023M |
| OnKure Therapeutics, Inc. | -9.87M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -24.22M |
| Cash from Financing (Quarterly) | 0.676M |
| Free Cash Flow | -93.90M |
| Free Cash Flow Per Share (Quarterly) | -0.3276 |
| Free Cash Flow to Equity (Quarterly) | -22.94M |
| Free Cash Flow to Firm (Quarterly) | -24.41M |
| Free Cash Flow Yield | -45.36% |